InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,576.98
(
0.07%
)
US TECH 100
19,968.80
(
0.29%
)
Dow Jones
39,291.97
(
-0.13%
)
Brent Oil
84.17
(
-0.62%
)
Bitcoin
58,612.97
(
1.02%
)
Post# of 6405
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zorro77

Send PM Follow Ignore
Followers 0
Posts 53
Boards Moderated 0
Alias Born 03/20/2011

zorro77

Re: zorro77 post# 5799

Thursday, 01/12/2012 10:30:27 AM

Thursday, January 12, 2012 10:30:27 AM

Post# of 6405
Gleevec or Imatinib is the first member of a new class of agents that act by specifically inhibiting a certain enzyme that is characteristic of a particular cancer cell for CML Leukemia, rather than non-specifically inhibiting and killing all rapidly dividing cells, this is a "targeted therapy" which kills only the cancer cells.
"Targeted Cancer Therapies" are the future of Oncology. My website shows these programs that will revolutionize Oncology and the Pharmaceutical Industry (the worlds largest industry).
My website; http://www.biologicalcancertreatments.com/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up